Oppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)

In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group, with a price target of $150.00. The company’s shares closed yesterday at $116.07.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Kalia is a 5-star analyst with an average return of 9.5% and a 54.13% success rate. Kalia covers the Healthcare sector, focusing on stocks such as PROCEPT BioRobotics, TransMedics Group, and Boston Scientific.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TransMedics Group with a $142.56 average price target, which is a 22.82% upside from current levels. In a report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $131.00 price target.

Based on TransMedics Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $157.37 million and a net profit of $34.91 million. In comparison, last year the company earned a revenue of $114.31 million and had a net profit of $12.19 million

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2025, Waleed H Hassanein, the President & CEO of TMDX bought 16,875.00 shares for a total of $1,982,120.66.